ClinicalTrials.gg
CompletedNCT02079506Updated Mar 5, 2014

Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin

A Phase 1 interventional study of Candesartan and Rosuvastatin in Healthy, sponsored by Alvogen Korea. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-05.

Sponsored by Alvogen Korea (part of Lotus Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The objective of this study is to compare pharmacokinetics after single oral administration of candesartan and rosuvastatin each separately versus coadministration of candesartan and rosuvastatin in healthy male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Alvogen Korea is the lead sponsor of 24 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers af aged between 20 years to 45 years
  • Have a weight above 55kg and Ideal body weight (IBW) between -20% and +20% inclusive
  • Eligible subjects with acceptable medical history and physical examination

Exclusion criteria

Exclusion Criteria:

  • Have a known or history of hypersensitivity to drugs including the same class drugs with candesartan or rosuvastatin, or other drugs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Treatment A

    Drug: Candesartan

  • Experimental
    Treatment B

    Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss of candesartan

    0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h

    Time frame: 22 points

  2. Cmax,ss of candesartan

    0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h

    Time frame: 22 points

  3. AUCτ,ss of rosuvastatin

    0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h

    Time frame: 28 points

  4. Cmax,ss of rosuvastatin

    0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h

    Time frame: 28 points

Secondary outcomes

  1. tmax,ss of candesartan

    0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h

    Time frame: 22 points

  2. CLss/F of candesartan

    0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h

    Time frame: 22 points

  3. Cmin,ss of candesartan

    0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h

    Time frame: 22 points

  4. tmax,ss of rosuvastatin

    0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h

    Time frame: 28 points

  5. CLss/F of rosuvastatin

    0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h

    Time frame: 28 points

  6. Cmin,ss of rosuvastatin

    0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h

    Time frame: 28 points

07

Study locations

1 site
  • Chungnam National University Hospital
    Jung-gu, Daejeon 301-721, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2014
First posted
Mar 5, 2014
Start
Feb 2014
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Last update
Mar 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02079506
Lead sponsor
Alvogen Korea
Responsible party
Sponsor
First posted
Mar 5, 2014
Start date
Feb 2014
Primary completion
Feb 2014
Completion
Feb 2014
Last update
Mar 5, 2014

Study contacts

JangHee Hong, PhD.
principal investigator · Chungnam National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Candesartan · Rosuvastatin

Start the discussion